MBQ-167 NEW
| Price | $31 | $44 | $72 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: MBQ-167 | CAS No.: 2097938-73-1 |
| Purity: 98.74% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | MBQ-167 |
| Description | MBQ-167 is a dual inhibitor of Rac/Cdc42 (IC50s: 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively). |
| In vitro | MBQ-167 causes this phenotype in multiple mesenchymal cancer cell types including GFP-HER2-BM, MDA-MB-468, and Hs578t human breast cancer cells, as well as Mia-PaCa-2 pancreatic cancer cells, SKOV3 ovarian cancer cells, AGS and NCI-N87 gastric cancer cells, and SH-SY5Y neuroblastoma cells. MBQ-167 (≥100 nM) causes a loss of polarity in metastatic breast cancer cells. MBQ-167(500 nM; 24 h)treatment, results in ~95% cell rounding and detachment from the substratum in metastatic MDA-MB-231 cells. At earlier times (6h), MBQ-167(250 or 500 nM)treatment, induce an inhibition in Rac activity in the attached cell population, while the detached population demonstrates a ~40-50% inhibition. The attached population of MDA-MB-231 cells demonstrate a ~25% decrease in Rac activation while the detached cells are more responsive with a ~75% decrease following treatment with 250 nM MBQ-167 for 24 h . |
| In vivo | Mice treated with MBQ-167 exhibited comparable doubling times for the treatments (10 and 11 days), and demonstrated a statistically significant decrease in tumor growth. Upon sacrifice, a dosage of 1.0 mg/kg body weight (BW) with MBQ-167 led to an approximate 80% reduction in tumor size, while a higher dose of 10 mg/kg BW achieved an approximate 95% reduction. In comparison, EHop-016 at a 10 mg/kg BW dosage resulted in about a 40% reduction in tumor growth, making MBQ-167 ten times more effective than EHop-016. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 0.1 mg/mL (insoluble) DMSO : 155 mg/mL (458.02 mM), Sonication is recommended. |
| Keywords | Cyclin dependent kinase | Inhibitor | inhibit | MBQ167 | CDK | Ras | MBQ 167 | MBQ-167 |
| Inhibitors Related | Ribociclib | Ketoconazole | MRTX1133 | Salirasib | RMC-6236 | CASIN | Palbociclib | Sodium Oxamate | Abemaciclib | Sotorasib | Dinaciclib | Abemaciclib methanesulfonate |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | HIF-1 Signaling Pathway Compound Library | Kinase Inhibitor Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $682.00/200μg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-18 | |
| $2300.00/1mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $88.00/1EA |
Amikon Limited
|
2018-07-12 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY